{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:48:06Z","timestamp":1792399686512,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000683","name":"Royal Society of Tropical Medicine and Hygiene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bedaquiline improves culture conversion in drug-resistant tuberculosis (DR-TB) treatment; its main safety concern is QTc prolongation, particularly when combined with other anti-TB drugs. This study assessed the incidence and predictors of QTc prolongation among DR-TB patients receiving bedaquiline under programmatic conditions in Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using medical records from 14 DR-TB treatment sites across Uganda (January 2017\u2013December 2022). Data on demographics, clinical characteristics, bedaquiline-based regimens, treatment duration, and QTc intervals were collected. Incidence rates with 95% CIs were calculated for QTc prolongation, while modified Poisson regression was used to identify predictors of QTc prolongation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were abstracted from 532 patients, 70.9% of whom were male. The mean (SD) age was 41.4 (15.9) years, and 34.6% were coinfected with HIV. The baseline mean (SD) QTc was 426.8 (28.4) ms, with a median follow-up (interquartile range) of 10.3 (7.2\u201313.5) months. The overall incidence of QTc prolongation was 12.0 cases per 1000 person-months (95% CI, 10.8\u201316.8). Lower body mass index (BMI; incidence rate ratio [IRR], 0.924; 95% CI, 0.860; IRR, 0.993; P = .031) increased risk of QTc prolongation. Treatment success was similar among patients with and without QTc prolongation: 73.9% (51\/69) vs 68.3% (316\/463); P = .873.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An average of 12 new cases of QTc prolongation was observed for every 1000 person-months of accumulated observation time. The recommended monthly electrocardiogram monitoring should be emphasized among patients with low baseline BMI. QTc prolongation was not linked to poor treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag637","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:49:34Z","timestamp":1790855374000},"source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Predictors of QTC Prolongation Among Drug-Resistant Tuberculosis Patients Receiving Bedaquiline-Based TB Regimens in Uganda: A Countrywide Retrospective Cohort Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-2499","authenticated-orcid":false,"given":"Marble","family":"Nasasira","sequence":"first","affiliation":[{"name":"Child and Family Foundation , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-3926","authenticated-orcid":false,"given":"Kevin Ouma","family":"Ojiambo","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit, School of Medicine, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]},{"name":"Uganda Institute of Public Health, Ministry of Health , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Iraguha","sequence":"additional","affiliation":[{"name":"Division of Adult Cardiology, Uganda Heart Institute , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-9674","authenticated-orcid":false,"given":"Joseph Baruch","family":"Baluku","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Kiruddu National Referral Hospital , Kampala ,","place":["Uganda"]},{"name":"Makerere University Lung Institute , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026101904315263000_ofag637-B1","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO's global tuberculosis report 2022","volume":"4","author":"Bagcchi","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026101904315263000_ofag637-B2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13756-021-00947-2","article-title":"Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014\u20132018","volume":"10","author":"Bahizi","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026101904315263000_ofag637-B3","volume-title":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment, 2022 Update","author":"World Health Organization","year":"2022"},{"key":"2026101904315263000_ofag637-B4","volume-title":"WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment","author":"Cocco","year":"2019"},{"key":"2026101904315263000_ofag637-B5","volume-title":"Addendum to the National Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis.","author":"Ministry of Health Uganda","year":"2019"},{"key":"2026101904315263000_ofag637-B6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"2026101904315263000_ofag637-B7","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"van Heeswijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026101904315263000_ofag637-B8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/jpet.302.1.320","article-title":"Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics","volume":"302","author":"Volberg","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2026101904315263000_ofag637-B9","article-title":"Effects of bedaquiline combined with fluoroquinolone and\/or clofazimine on QT interval in patients with multidrug-resistant tuberculosis: a retrospective study","volume":"11","author":"Li","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026101904315263000_ofag637-B10","volume-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis","author":"World Health Organization.","year":"2014"},{"key":"2026101904315263000_ofag637-B11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1515\/jbcpp-2020-0415","article-title":"Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients","volume":"32","author":"Ardhianto","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"2026101904315263000_ofag637-B12","volume-title":"WHO Consolidated Operational Handbook on Tuberculosis. Module 4: Treatment and Care","author":"World Health Organization.","year":"2025"},{"key":"2026101904315263000_ofag637-B13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/aje\/kwg074","article-title":"Estimating the relative risk in cohort studies and clinical trials of common outcomes","volume":"157","author":"McNutt","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2026101904315263000_ofag637-B14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1590\/S0034-89102008000600003","article-title":"Methods for estimating prevalence ratios in cross-sectional studies","volume":"42","author":"Coutinho","year":"2008","journal-title":"Rev Saude Publica"},{"key":"2026101904315263000_ofag637-B15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2288-3-21","article-title":"Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio","volume":"3","author":"Barros","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"2026101904315263000_ofag637-B16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab413","article-title":"QT interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis under programmatic conditions: a retrospective cohort study","volume":"8","author":"Isralls","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026101904315263000_ofag637-B17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01181-2019","article-title":"A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis","volume":"55","author":"Olayanju","year":"2020","journal-title":"Eur Respir J"},{"key":"2026101904315263000_ofag637-B18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1473-3099(18)30100-2","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026101904315263000_ofag637-B19","article-title":"Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California","volume":"23","author":"Katrak","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026101904315263000_ofag637-B20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/cid\/ciae601","article-title":"The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant\/rifampicin-resistant tuberculosis cohort","volume":"81","author":"Khan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026101904315263000_ofag637-B21","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"2026101904315263000_ofag637-B22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026101904315263000_ofag637-B23","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciac876","article-title":"Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"76","author":"Holmgaard","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026101904315263000_ofag637-B24","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad213","article-title":"Manual vs. automatic assessment of the QT-interval and corrected QT","volume":"25","author":"Neumann","year":"2023","journal-title":"Europace"},{"key":"2026101904315263000_ofag637-B25","first-page":"140","article-title":"Bedaquiline correlation to QT interval prolongation in DR-TB patients","volume":"8","author":"Primadana","year":"2022","journal-title":"J Resp"},{"key":"2026101904315263000_ofag637-B26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/ijmy.ijmy_178_22","article-title":"Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis","volume":"11","author":"Putra","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"2026101904315263000_ofag637-B27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijtb.2020.03.002","article-title":"Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients","volume":"67","author":"Barvaliya","year":"2020","journal-title":"Indian J Tuberc"},{"key":"2026101904315263000_ofag637-B28","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/psp4.12722","article-title":"Exposure\u2013safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis","volume":"10","author":"Tanneau","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026101904315263000_ofag637-B29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/FTD.0000000000001164","article-title":"Effect of bedaquiline and delamanid pharmacokinetics on sputum culture conversion and adverse events in drug-resistant tuberculosis","volume":"46","author":"Bhatnagar","year":"2024","journal-title":"Ther Drug Monit"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag637\/71605857\/ofag637.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag637\/71605857\/ofag637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag637\/71605857\/ofag637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:32:03Z","timestamp":1792398723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag637\/8865220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag637","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,29]]},"article-number":"ofag637"}}